适应CUT&RUN用于非洲试生体的应用
Geneva Miller1, Lindsey M Rollosson1, Carrie Saada1
1Harvey Mudd College, Claremont, CA, United States of America.
PloS one
|November 21, 2023
概括
这项研究详细介绍了一种用于绘制Trypanosoma brucei中蛋白质位置的新方法,Trypanosoma brucei是一种导致睡眠疾病的寄生虫. 使用核酶 (CUT&RUN) 的切割目标下和释放技术为研究这种生物体的研究人员提供了基因组占用数据.
科学领域:
- 分子生物学分子生物学
- 寄生虫学的寄生虫学
- 基因组学就是基因组学.
背景情况:
- 虫 (Trypanosoma brucei) 是一种原生动物寄生虫,会引起人类和动物的重大疾病.
- 了解蛋白质-DNA相互作用对于破译T. brucei.中的基因调节至关重要.
- 现有的基因组占用分析方法可能是资源密集型或有局限性.
研究的目的:
- 为Trypanosoma brucei建立和验证一个Cleavage Under Targets和释放使用核酶 (CUT&RUN) 协议.
- 为了生成可靠的基因组占用数据,对这种寄生虫感兴趣的蛋白质.
- 提供一种可访问的方法来分析T. brucei基因组中的蛋白质结合位.
主要方法:
- 适应CUT&RUN协议用于原生虫寄生虫Trypanosoma brucei的使用.
- 利用表位标记蛋白或对抗原蛋白的抗体进行向丰富.
- 分析所得到的基因组占用数据,可与ChIP-seq方法相比较.
主要成果:
- 在Trypanosoma brucei.中成功实施了CUT&RUN协议.
- 为向蛋白质生成高质量的基因组占用概况.
- 证明该协议对研究这种寄生虫中的蛋白质-DNA相互作用的实用性.
结论:
- 该CUT&RUN协议提供了一个强大的方法来调查Trypanosoma brucei基因组中的蛋白质占用.
- 这种技术有助于更深入地了解基因调节和寄生虫生物学.
- 该协议可适应具有或没有现有表位标签的蛋白质,从而提高了其广泛的适用性.
相关概念视频
01:16Transduction
Among the three main modes of HGT—transformation, conjugation, and transduction—transduction is unique in that it is mediated by bacteriophages, or bacterial viruses.Transduction occurs in two ways. Generalized transduction occurs during the lytic cycle of a bacteriophage infection. In this process, bacteriophages infect bacterial cells, replicate within them, and ultimately cause cell lysis, releasing newly assembled virions. Occasionally, random fragments of the bacterial genome are...
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...